Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) rose 5.2% during trading on Thursday . The company traded as high as $4.19 and last traded at $4.02. Approximately 518,674 shares traded hands during mid-day trading, an increase of 200% from the average daily volume of 172,762 shares. The stock had previously closed at $3.82.

Separately, ValuEngine cut Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 24th.

The firm’s market capitalization is $210.52 million. The stock has a 50 day moving average price of $3.66 and a 200-day moving average price of $3.86.

In other Nymox Pharmaceutical Corporation news, Director James George Robinson bought 15,000 shares of the stock in a transaction on Wednesday, June 21st. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $56,550.00. Following the completion of the acquisition, the director now owns 3,008,150 shares in the company, valued at approximately $11,340,725.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders acquired 98,000 shares of company stock valued at $375,725. 54.00% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. State Street Corp bought a new stake in Nymox Pharmaceutical Corporation in the second quarter worth approximately $1,323,000. Wedbush Securities Inc. increased its holdings in Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 55,000 shares in the last quarter. TIAA CREF Investment Management LLC bought a new stake in Nymox Pharmaceutical Corporation in the second quarter worth approximately $329,000. Bank of New York Mellon Corp bought a new stake in Nymox Pharmaceutical Corporation in the second quarter worth approximately $323,000. Finally, Vanguard Group Inc. bought a new stake in Nymox Pharmaceutical Corporation in the second quarter worth approximately $302,000. Institutional investors and hedge funds own 5.79% of the company’s stock.

WARNING: This piece of content was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/14/nymox-pharmaceutical-corporation-nymx-stock-price-up-5-2.html.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.